Accro Bioscience to Present Phase Ib Data of AC-101, an Oral Selective RIPK2 Inhibitor, for Moderate-to-Severe UC at UEG Week 2026 in Barcelona
NEW YORK and SUZHOU, China, Aug. 13, 2026 /PRNewswire/ -- Accro Bioscience, a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, today announced that it will present efficacy and...
Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases
F inancing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza Proceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis NEW YORK and SUZHOU,...
Accropeutics Announces Positive Data from Phase 2 Trial of AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment of Moderate-to-Severe Plaque Psoriasis
Phase 2 primary endpoint of PASI-75 and key secondary endpoints met in all of the three dosing groups at Week 12 AC-201 was generally well tolerated at all dose levels with no SAEs or AEs leading to discontinuation Efficacy and safety findings from...